Skip to main content

Table 3 Therapy in patients whose tumors had low and high-grade infection with human cytomegalovirus Immediate-early (IEA) and late antigen (LA)

From: Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study

Therapy

Low-grade HCMV-IEA (n = 19)

High-grade HCMV-IEA (n = 61)

Low-grade HCMV-LA (n = 33)

High-grade HCMV-LA (n = 47)

Gamma knife

7 (37%)

10 (16.4%)

10 (30%)

7 (15%)

RT + adjuvant chemotherapy

7 (37%)

28 (46%)

14 (42%)

21 (45%)

Adjuvant chemotherapy

2 (11%)

7 (11%)

2 (6%)

7 (15%)

RT + Temozolomide

2 (11%)

8 (13%)

4 (12%)

6 (13%)

RT

1 (5.3%)

3 (5%)

1 (3%)

3 (6%)

RT + Lumostin

0 (0%)

1 (2%)

0 (0%)

1 (2%)

RT + IRESSA

0 (0%)

2 (3%)

2 (6%)

0 (0%)

Cortisone

0 (0%)

1 (2%)

1 (3%)

0 (0%)

Palliative therapy

0 (0%)

4 (7%)

1 (3%)

3 (6%)